Investment Partners LTD. trimmed its position in Pfizer Inc. (NYSE:PFE) by 6.6% during the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 30,941 shares of the biopharmaceutical company’s stock after selling 2,176 shares during the quarter. Investment Partners LTD.’s holdings in Pfizer were worth $1,123,000 as of its most recent SEC filing.

Other large investors have also recently bought and sold shares of the company. Ballew Advisors Inc acquired a new position in shares of Pfizer in the 1st quarter worth approximately $102,000. Earnest Partners LLC acquired a new position in shares of Pfizer in the 4th quarter worth approximately $105,000. Woodard & Co. Asset Management Group Inc. ADV acquired a new position in shares of Pfizer in the 4th quarter worth approximately $118,000. Delpha Capital Management LLC acquired a new position in shares of Pfizer in the 4th quarter worth approximately $126,000. Finally, W.G. Shaheen & Associates DBA Whitney & Co acquired a new position in shares of Pfizer in the 1st quarter worth approximately $132,000. Institutional investors own 68.91% of the company’s stock.

In other Pfizer news, EVP Kirsten Lund-Jurgensen sold 20,942 shares of the stock in a transaction that occurred on Wednesday, August 1st. The shares were sold at an average price of $40.04, for a total value of $838,517.68. Following the sale, the executive vice president now directly owns 20,185 shares of the company’s stock, valued at approximately $808,207.40. The sale was disclosed in a legal filing with the SEC, which is available at the SEC website. Also, CEO Ian C. Read sold 486,753 shares of the stock in a transaction that occurred on Monday, July 16th. The shares were sold at an average price of $37.36, for a total transaction of $18,185,092.08. Following the completion of the sale, the chief executive officer now directly owns 1,145,693 shares in the company, valued at $42,803,090.48. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 761,230 shares of company stock worth $29,054,690. 0.06% of the stock is owned by insiders.

Shares of PFE opened at $43.93 on Tuesday. Pfizer Inc. has a fifty-two week low of $33.20 and a fifty-two week high of $44.46. The company has a market cap of $262.28 billion, a P/E ratio of 16.58, a price-to-earnings-growth ratio of 2.23 and a beta of 0.96. The company has a current ratio of 1.16, a quick ratio of 0.91 and a debt-to-equity ratio of 0.41.

Pfizer (NYSE:PFE) last announced its earnings results on Tuesday, July 31st. The biopharmaceutical company reported $0.81 earnings per share for the quarter, topping the consensus estimate of $0.74 by $0.07. Pfizer had a net margin of 42.35% and a return on equity of 25.35%. The firm had revenue of $13.47 billion for the quarter, compared to the consensus estimate of $13.30 billion. During the same period in the prior year, the firm earned $0.67 EPS. The firm’s revenue for the quarter was up 4.4% on a year-over-year basis. research analysts forecast that Pfizer Inc. will post 2.99 earnings per share for the current fiscal year.

The firm also recently announced a quarterly dividend, which was paid on Tuesday, September 4th. Investors of record on Friday, August 3rd were paid a dividend of $0.34 per share. This represents a $1.36 annualized dividend and a yield of 3.10%. The ex-dividend date was Thursday, August 2nd. Pfizer’s payout ratio is currently 51.32%.

Several equities analysts have recently commented on PFE shares. Credit Suisse Group upped their price objective on shares of Pfizer from $39.00 to $40.00 and gave the stock a “neutral” rating in a report on Wednesday, August 1st. Morgan Stanley set a $45.00 price objective on shares of Pfizer and gave the stock a “buy” rating in a report on Wednesday, August 29th. Bank of America upped their price objective on shares of Pfizer from $42.00 to $43.00 and gave the stock a “buy” rating in a report on Wednesday, August 1st. JPMorgan Chase & Co. restated a “$37.66” rating on shares of Pfizer in a report on Wednesday, July 18th. Finally, Zacks Investment Research lowered shares of Pfizer from a “buy” rating to a “hold” rating in a report on Sunday, July 15th. Two research analysts have rated the stock with a sell rating, twelve have given a hold rating and nine have assigned a buy rating to the company’s stock. Pfizer currently has a consensus rating of “Hold” and a consensus target price of $41.89.

About Pfizer

Pfizer Inc discovers, develops, manufactures, and sells healthcare products worldwide. It operates in two segments, Pfizer Innovative Health (IH) and Pfizer Essential Health (EH). The IH segment focuses on the development and commercialization of medicines and vaccines, and consumer healthcare products in various therapeutic areas, including internal medicine, vaccines, oncology, inflammation and immunology, and rare diseases, as well as consumer healthcare, such as over-the-counter brands comprising dietary supplements, pain management, gastrointestinal, and respiratory and personal care.

Featured Article: How to Track your Portfolio in Google Finance

Institutional Ownership by Quarter for Pfizer (NYSE:PFE)

Receive News & Ratings for Pfizer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer and related companies with MarketBeat.com's FREE daily email newsletter.